On August 23, 2024, MEBO Group and the China Leprosy Prevention Association (CLPA) initiated a transformative charity project focused on treating hard-to-heal wounds in individuals affected by leprosy. The launch ceremony in Yantai, Shandong, signified a milestone in the partnership, highlighting their shared commitment to improving healthcare for marginalized communities.

Key Leaders Attend the Historic Ceremony

The event saw the participation of prominent figures, including MEBO Group’s President Yang Zhibin, Vice President Chen Baoqi, and Director of Public Service Development Center Zhang Kun, alongside CLPA’s President Zhang Furen and Vice President Pan Chunzhi. Their involvement emphasized the project’s importance and the potential for impactful change.

Strategic Collaboration for Improved Healthcare

Post-ceremony, an in-depth discussion ensued with leprosy prevention experts from five provinces—Shaanxi, Yunnan, Jiangsu, Sichuan, and Hunan. MEBO Group pledged extensive resources for technical training, clinical treatment, and financial aid. This initiative will ensure local medical professionals receive advanced training while providing targeted care for disadvantaged patients.

Expanding the Partnership for Broader Impact

MEBO Group and CLPA aim to expand their collaboration, focusing on "cooperative development, resource sharing, and mutual benefit." This partnership aligns with China’s 2024-2030 plan to eliminate leprosy hazards, demonstrating MEBO Group’s dedication to its humanitarian mission and leadership in regenerative medicine. This partnership not only represents a major step forward in patient care but also highlights MEBO Group's enduring commitment to social responsibility and public welfare.

About MEBO

Founded in 1987 by Professor Rongxiang Xu, a distinguished Chinese life scientist, MEBO Group is a multinational headquartered in both China and the USA. It integrates research, development, and sales across the pharmaceuticals, medical devices, health foods, and cosmetics sectors.

At its core, MEBO focuses on regenerative life sciences, innovating with over 100 patents and more than ten joint research bases to enhance and enable the body's own regenerative abilities.

As a leader in regenerative life science, MEBO's extensive research facilities and products impact over 100 countries globally, pioneering new frontiers in the regenerative life world.